Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 6,55€(−9,78%). Der Median liegt bei 5,80€(−20,11%).
Kaufen | 5 |
Halten | 1 |
Verkaufen | 2 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website.» Mehr auf accessnewswire.com
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr.» Mehr auf businesswire.com
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.» Mehr auf seekingalpha.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 44,66 Mio | 27,04% |
Bruttoeinkommen | 33,53 Mio | 127,96% |
Nettoeinkommen | −84,08 Mio | 45,31% |
EBITDA | −63,16 Mio | 58,72% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 416,59 Mio€ |
Anzahl Aktien | 58,53 Mio |
52 Wochen-Hoch/Tief | 33,25€ - 4,46€ |
Dividenden | Nein |
Beta | 1,3 |
KGV (PE Ratio) | −0,92 |
KGWV (PEG Ratio) | −0,06 |
KBV (PB Ratio) | 0,67 |
KUV (PS Ratio) | 1,97 |
Unternehmensprofil
Name | Ginkgo Bioworks Holdings A Aktie |
CEO | Dr. Jason Kelly Ph.D. |
Mitarbeiter | 834 |
Assets entdecken
Shareholder von Ginkgo Bioworks Holdings A Aktie investieren auch in folgende Assets